Chronic Allograft Dysfunction: A Model Disorder of Innate Immunity

Walter Gottlieb Land

The innate immune system is a highly sensitive organ of perception sensing any cell stress and tissue injury. Its major type of response to all potential inciting and dangerous challenges is inflammation and tissue repair and, if needed, induction of a supportive adaptive immune response, the aim always being to maintain homeostasis. However, although initially beneficial, innate immunity-mediated, protection-intended repair processes become pathogenic when they are exaggerated and uncontrolled, resulting in permanent fibrosis which replaces atrophic or dying tissue and may lead to organ dysfunction or even failure. In this sense, atherosclerosis and organ fibrosis reflect classical disorders caused by an overreacting innate immune system. Strikingly, these two pathologies dominate the development of chronic allograft dysfunction as the main clinical problem still left in transplantation medicine. Growing evidence suggests that acute and chronic allograft injuries, including alloimmune-, isoimmune-, nonimmune-, and infection-mediated insults, not only lead to cell death–associated graft atrophy but also activate the innate immune system which, over time, leads to uncontrolled intragraft fibrogenesis, thereby compromising allograft function. Acute and chronic allograft injuries lead to induction of damage-associated molecular patterns (DAMPs) which, after recognition by pattern recognition receptors, activate cells of the innate immune system such as donor-derived intragraft fibroblasts and vascular cells as well as recipient-derived graft-invading macrophages and leukocytes. It is mainly the orchestrated action and function of these cells that slowly but steadily metamorphose the originally life-saving allograft into a poorly functioning organ of marginal viability. ([Biomed J 2013;36:209-228])

Key words: allograft injuries, atherogenesis, chronic allograft dysfunction, damage-associated molecular patterns, fibrogenesis, innate immunity

A decade ago, we proposed that chronic allograft rejection, also called as chronic allograft dysfunction (CAD), results from antigen-dependent and antigen-independent allograft injuries that elicit innate immune responses leading to fibrotic processes in the allograft as reflected by alloatherosclerosis and allofibrosis.[1,2] In view of incredible progress in research on innate immunity, it is becoming apparent that our concept is largely true. Accordingly, in this article, recent evidence is collected in support of the notion that the etiopathogenesis of CAD – besides progressive loss of parenchymal cells – is dominated by the processes of the donor’s and recipient’s innate immune system activated by various types of acute and chronic allograft injuries.

In the past, the innate immune system was primarily seen as a host defense system with its primary task to eliminate the invading pathogens. However, these views have changed. Today, the system is regarded as a highly sensitive organ of perception sensing any cell stress and tissue injury. The system’s major type of response to all these different inciting and dangerous challenges is inflammation.[3] The aim of the response
is to provide any kind of protection including killing of invading pathogens, removing dead cells, repairing destroyed tissue, balancing metabolic or psychological irregularities, and finally, when foreign antigens are involved (such as microbial antigens, altered self-antigens, or alloantigens), inducing a supportive adaptive immune response. However, although initially beneficial, these innate immunity-mediated, protection-intended tissue repair processes become pathogenic when they are exaggerated and uncontrolled, resulting in deregulated cell differentiation and proliferation as well as substantial deposition of extracellular matrix (ECM) components in which severely damaged, atrophic, or dying tissue is replaced with permanent fibrotic tissue [Figure 1].

Thus, histology of chronically deteriorating allograft function, as for example observed in renal,[14] heart,[9] and lung transplantation,[6] is dominated by a variety of fibrosing changes in the (micro) vasculature (alloatherosclerosis) and the interstitium (allofibrosis), often seen in the absence of acute inflammatory cellular infiltrates. Accordingly, CAD may be regarded as a model disorder of injury-induced, innate immunity-mediated atherosclerosis and organ fibrosis as a consequence of allograft injury-induced cell death and atrophy. The unique feature of this model is the fact that the innate immune system is activated by both immune and nonimmune allograft injuries.

In order to cover this topic, recent selected data from the exploding international literature are explored by highlighting innate immune mechanisms reported to be involved in injury-induced atherogenesis and fibrogenesis. Of note, because of space limitations, most references are review articles in which the original citations can be found.

**Injury-induced, innate immunity-mediated infectious and “sterile” inflammation**

Current notions in immunology hold that not only pathogen-mediated injury but also any tissue injury associated with cell damage activates the innate immune system that elicits an infectious or “sterile” inflammatory response. In fact, the phenomenon that “injury induces immunity” was discovered by our group two decades ago[32,39] and was intrinsically designed and described by Matzinger within her famous danger theory.[10,11] Whilst infectious tissue injury is associated with the presence of pathogen-associated molecular patterns (PAMPs),[10] non–pathogen-mediated injury leads to the induction of so-called damage-associated molecular patterns, the DAMPs, as first described by us in 2003. Notably, tissue-damaging infectious pathogens may even induce DAMPs that finally trigger a vigorous anti-pathogen innate immune response [Figure 2].[13,14] DAMPs, like PAMPs sensed by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs), include the prototypic high-mobility group box 1 (HMGB1), heat shock proteins (HSPs), oxidized/minimally modified low-density lipoproteins (oxLDL/mmLDL), as well as endogenous DNA and RNA released from dying cells.[15-17]

Of note, the development of infectious and sterile inflammation, and also inflammation-mediated atherosclerosis and fibrosis is promoted – though not exclusively – by the function of inflammasomes, the two most extensively studied being the NLR-containing pyrin domain 3 (NLRP3) and the absent in melanoma 2 (AIM2) inflammasome. The characteristic function of these “molecular machines” of the innate immune system is to secrete interleukin-1 beta (IL-1β) and IL-18 that mature from their proforms to bioactive cytokines through proteolytic cleavage by caspase-1.[18-21] Modern notions hold that full function of the NLRP3 inflammasome is a two-step process. The first step, the priming step, consists of stimulation of PRRs such as TLRs and leads, via transcriptional processes, to the up-regulation of NLRP3 and expression of pro-IL-1β and pro-IL-18 in the cytosol. The activation step is distinct from this initial priming step and reportedly mediated by various mechanistic pathways. Certain DAMPs such as reactive oxygen species (ROS)-induced oxidized proteins or extracellular adenosine triphosphate (eATP), uric acid, and nucleic acids (endogenous DNA, RNA) known to be released from damaged or dying cells appear to play a critical role in the activation of the NLRP3 inflammasome, with the double-stranded RNA-dependent protein kinase (PKR) also being shown
to be involved recently [Figure 3]. Nevertheless, the exact activating mechanism is still elusive; probably, any, even the slightest intra- or extracellular alteration of the microenvironment may activate this inflammasome.

**Innate immunity and atherosclerosis**

Atherosclerosis is a chronic inflammatory disease in which both innate and adaptive (auto) immune mechanisms are involved [Figure 4]. The atherosclerotic plaque characterizes by an accumulation of lipids in the artery wall, together with infiltration of immune cells such as macrophages, mast cells, and T cells, and the formation of a fibrous cap composed mostly of collagen by vascular smooth muscle cells (VSMCs). The innate immune system of the normal artery represents the starting point of atherogenesis by responding to any inciting agent including oxidative, metabolic, mechanical, biotoxic, or infectious stress. PRR-bearing sessile cells such as endothelial cells (ECs) and VSMCs, exposed to injurious challenges, mount a primary inflammatory response in the arterial wall that is secondarily aggravated by the action of mobile cells such as macrophages, neutrophils, mast cells, and dendritic cells (DCs) infiltrating the subendothelial space. This process is associated with the transformation of quiescent contractile VSMCs that proliferate and migrate to the neointima where they produce ECM proteins leading to accumulation of fibrous tissue – a process that is pivotal for the onset and progression of atherosclerosis.

**DAMPs/PAMPs–PRRs engagement in atherosclerotic inflammation**

Numerous studies have identified oxidative stress-induced DAMPs as the major activators of vascular inflammation leading to atherosclerosis. Thus, atherogenesis starts with subendothelial retention and accumulation of circulating low-density lipoprotein (LDL) that undergoes various oxidative modifications. During the progression of atherosclerosis, most of these ROS-induced DAMPs are found in various forms of oxLDL and mmLDL. Further, oxidation-specific epitopes, for example, those derived from oxLDL, appear to play a prominent role by forming a distinct family of DAMPs consisting of various categories of oxidative reactions. Oxidation-specific epitopes that also possess antigenic properties operate as ligands for a common set of PRRs including natural IgM antibodies, their binding leading to activation of the complement cascade.

Other injury-induced DAMPs such as HSPs and HMGB1 known to bind to the receptor for advanced glycation end products (RAGE), TLR4 and TLR2 on vascular cells, are also involved in establishing a vascular inflammatory cascade contributing to atherogenesis. Of note, DAMPs such as HMGB1 and mmLDL were shown to participate in...
VSMC phenotype transformation, as HSP70 was found to increase ECM production by human VSMCs through up-regulation of transforming growth factor-beta1 (TGF-β1) expression. These observations indicate a direct role of DAMPs in the establishment of neointima formation leading to arterial wall remodeling [Figure 4].

Besides DAMPs, a number of various PRRs including TLRs, NLRs, and RAGE were shown to mediate atherosclerotic inflammation and contribute to plaque formation. Of particular interest amongst those receptors is the lectin-like oxidized LDL receptor-1 (LOX-1) that was found to be expressed in ECs and VSMCs and to be highly up-regulated in atherosclerosis.

The possibility that infectious agents via generation of PAMPs provoke relevant innate immune responses to arteries has been considered, but little evidence supports a primary impact, though contributory roles are possible. Accordingly, a large number of infectious agents reportedly have been linked with an increased risk of vascular disease, including *Chlamydia pneumonia*, *Porphyromonas gingivalis*, *Helicobacter pylori*, influenza A virus, herpes virus, hepatitis C virus (HCV), cytomegalovirus (CMV), and human immunodeficiency virus.

**Role of the NLRP3 inflammasome in atherogenesis**

Of note, the discovery of the inflammasome protein complex, located in both sessile and infiltrated vascular cells, has shed more light on the mechanisms involved in mounting vascular inflammation involved in atherogenesis. In particular, studies on murine and human phagocytes and in *vivo* settings revealed that crystals of cholesterol – operating as DAMPs – activate the NLRP3 inflammasome required for atherogenesis. Remarkably, more recent investigations in NLRP3-deficient mice...
provided evidence even indicating that the NLRP3 inflammasome plays a crucial, non-redundant role in vascular damage-mediated neointima formation. Activation of the NLRP3 inflammasome in these settings is not quite clear. Of interest, however, are studies suggesting that oxidative stress – in its own or via induction of oxLDL – may operate as the “priming” DAMP in the early course of NLRP3 activation [Figures 3 and 4].

Interplay between innate immunity and adaptive immunity in atherogenesis

Adaptive immunity is not a prerequisite for atherogenesis, but its presence profoundly affects lesion formation and, on balance, is proatherogenic. Indeed, extensive data now support the notion that T cells, mainly Th1 cells in conjunction with interferon-gamma (IFN-γ), mediate proinflammatory and proatherogenic immune responses. Current notions hold that immunostimulatory DCs in the arterial wall, activated after recognition of DAMPs through PRRs, engulf and process stress/innate injury-induced neoantigens in terms of altered/self-proteins generated in early atherosclerotic lesions (or systemically), such as the oxidatively modified apolipoprotein B-100 component of LDL, HSPs, and others. The vascular autostimulatory DCs, then, present these altered self-proteins as peptide/major histocompatibility complex (MHC) complexes to naïve T cells in secondary lymphoid tissue, leading to the initiation and induction of a specific adaptive Th17- and/or Th1 autoimmune response that, in terms of a vicious circle, may further aggravate the vascular injury. Note: Intracellular signaling pathways as sketched in the macrophage and the smooth muscle cell are illustrated in more detail in Figures 3 and 5.

Figure 4: Scenario model of vascular injury-induced, innate and adaptive immune responses involved in atherogenesis. Vascular innate immune cells, here illustrated by PRR-bearing, NLRP3 inflammasome-expressing vascular smooth muscle cells, macrophages, and dendritic cells, are activated by various classes of DAMPs induced by vascular injuries. All three cell types exert different innate immune functions which orchestrate a network of processes leading to atherosclerosis: (1) activated smooth muscle cells, after recognition of DAMPs by PRRs (including NLRP3), contribute to development of intima fibrosis via proliferation and phenotype transformation able to secrete extracellular matrix proteins; (2) macrophages, via function of the NLRP3 inflammasome (e.g., activated by “priming” HMGB1 and “activating” cholesterol), contribute to creation of vessel wall inflammation; and (3) vascular dendritic cells, activated by recognition of DAMPs, engulf and process neoantigens (altered self-proteins) such as oxidation-specific epitopes, migrate to secondary lymphoid tissue, and present the peptide/MHC complex to naïve T cells. This leads to the initiation and induction of a specific adaptive Th17- and/or Th1 autoimmune response that, in terms of a vicious circle, may further aggravate the vascular injury.
Chronic allograft dysfunction: A model disorder of innate immunity

Walter Gottlieb Land

Innate immunity and fibrosis

Normal injury-induced, innate immune-mediated tissue repair can evolve into a progressively irreversible fibrotic response if the tissue injury is severe or repetitively chronic, or if the innate immune response becomes uncontrolled and exaggerated. “Fibrogenic” injury to tissues and organs can result from various inciting factors including chronic autoimmune responses, persistent infections, recurrent exposure to toxins, irritants, and mechanical injury, for example, mediated by hypertension.

The type of innate immune cells heavily involved in the extensive tissue damage and tissue repair is the fibroblast which operates as a sentinel cell and can be derived from resident fibroblasts, from circulating fibrocytes, or by epithelial–mesenchymal transition (EMT). Persistently activated fibroblasts called myofibroblasts mediate the excessive secretion of collagen in chronically injured organs and tissues. Myofibroblasts are phenotypically characterized by increased α-smooth muscle actin (α-SMA). The key molecule TGF-β, in concert with other profibrotic cytokines and downstream growth factors such as the connective tissue growth factor, can induce the full repertoire of fibrotic responses and plays a direct role in fibroblast proliferation/differentiation and deposition of ECM proteins. TGF-β is ubiquitously expressed and produced by multiple cell types in three isoforms (TGF-β1, -2, and -3) in mammals (T cells being its essential source), but is kept latent and bound mostly to ECM components by non-covalent association with its propeptide, the latency associated peptide (LAP). Thus, the activation of TGF-β, a crucial point of regulation in TGF-β function, is primarily regulated by conversion of latent TGF-β to active TGF-β and involves proteolysis of LAP or conformation changes of the latent TGF-β.

Role of the NLRP3 inflammasome in fibrogenesis

Recent studies on fibroblasts and different organs have convincingly demonstrated that the innate immune sensor NLRP3, mostly inflammasome dependent, but also inflammasome independent, plays a crucial role in fibrogenesis and can orchestrate profibrotic innate immune responses under both infectious and sterile conditions.
In fact, it is now significantly apparent that the key products of the NLRP3 inflammasome, IL-1β and IL-18, exert profibrotic activities. Studies on the experimental fibrosis model of bleomycin (BLM)-induced lung injury revealed a role of the DAMPs uric acid and eATP that are released from damaged cells and activate the NLRP3 inflammasome leading to IL-1β production and lung fibrosis. In associated studies on this model, it was shown that IL-1β production is dependent on TLR2, TLR4, myeloid differentiation primary response gene 88 (MyD88), and interleukin-1 receptor type 1 (IL-1R1) pathways.

Of note, mechanistic studies on the BLM model in deficient mice revealed the existence of an early IL-1β → IL-23 → IL-17 (IL-17A) axis leading to inflammation and fibrosis, probably via promotion of proliferation, transformation, and collagen synthesis of fibroblasts. Of note, recent studies lent support to the assumption that this axis operates upstream of the expression of TGF-β in terms of IL-1β-induced transcriptional activation of TGF-β, for example, via up-regulation of integrin αβ8 expression on the cell surface. Active TGF-β, in an auto-/paracrine manner, then, binds to fibroblast TGF-β receptors [Figures 5 and 6].

Further studies provided evidence indicating a role of IL-1β and IL-18, in synergy with IL-23, for the activation of gammadelta (γδ) T cells (including human γδ T cells), to secrete (early) proinflammatory IL-17A, that, in turn, promotes fibrogenesis. Besides γδ T cells, natural killer T (NKT) cells and certain populations of innate lymphoid cells – although less pronounced – have been shown to secrete proinflammatory IL-17A supposed to contribute to fibrogenesis. Receptor-triggered signaling pathways regulating IL-17 production by γδ T cells (as also by CD4+ Th17 cells, see below) were reportedly shown to include the transcription factors retinoic acid-related orphan receptor (RORγt) and signal transducer and activator of transcription 3 (STAT3).

**Interplay between innate immunity and adaptive (Th17) immunity in fibrogenesis**

It is increasingly becoming apparent that not only innate immune responses but also adaptive immune responses...
participate in the differentiation and activation of fibroblasts leading to fibrosis. Depending on both the nature of antigenic stimulus and the injurious environment, various adaptive immune pathways have been described.

Most importantly, there is increasing evidence indicating a critical proinflammatory and profibrotic role of the adaptive Th17-type immune response. In fact, CD4+ Th17 cells, secreting (late) proinflammatory cytokines IL-17A and IL-17F, are emerging as important drivers of fibrosis and were shown to contribute to the pathogenesis of many inflammatory and autoimmune diseases. The DC-dependent differentiation of Th17 cells is orchestrated by an intricate network of positive and negative polarizing cytokines and transcriptional regulators in T cells including STAT3-dependent RORγt and RORcT. In the center of this network, mitogen-activated protein kinases (MAPKs) (in particular, p38α MAPK) signaling and inflammasome activation have emerged as critical pathways to program TH17 cell differentiation by integrating multiple instructive DAMP-induced signals in DCs.

Accordingly, injury-induced, Th17-instructive DAMPs are sensed by PRRs on/in DCs which then drive Th17 cell differentiation by providing (auto) antigenic, costimulatory, and Th17-polarizing cytokine signals. The process to shape and stabilize Th17 development is mediated by (1) engulfment and processing by autostimulatory DCs of injury-induced neoantigens; (2) expression of selective costimulatory molecules enforced by CD40–CD40L ligation; (3) presence of Th17-polarizing, STAT3-activating cytokines, that is, IL-6, IL-23, and inflammasome-driven IL-1β/IL-18 mainly produced by DCs but also other innate immune cells; (4) TGF-β1 and IL-21 produced by activated T cells; and finally (5) TGF-β1 produced by Th17 cells themselves in an autocrine manner [Figure 7].

Taken together, also in view of the role of γδ T cells as mentioned above, these data identify the innate IL-1β → IL-23 → IL-17A ↔ TGF-β1 cytokine axis as an important pathway in inflammation-mediated, innate/adaptive immunity-driven fibrogenesis.
In addition to Th17-type responses, Th2-type immunity is also a potent key driver of progressive fibrosis. As reviewed, Th2 responses are defined by the production of IL-4, IL-5, and IL-13, while IL-13 has emerged as a dominant profibrotic cytokine that (independently of TGF-β) has been shown to mediate fibrotic tissue remodeling in several experimental and natural models of fibrosis. This suggests that unlike IL-17A but like TGF-β, IL-13 exerts direct fibrotic activity.

Allograft injury-induced, innate immunity-mediated chronic allograft dysfunction

There are multiple injuries to an allograft which, via induction of innate immune pathways, may lead to CAD [Table 1].

The nature of injuries varies, appears to be partially organ specific, and includes causative factors such as allo-


![Figure 7: Scenario model: injury-induced, innate immunity-activated (Th17) autoimmunity leading to fibrosis via establishment of an “IL-1β → IL-23 → IL-17A ↔ TGF-β1 cytokine axis.” Injury-induced, Th17-instructive DAMPs are sensed by PRRs on/in DCs, which then drive Th17 cell differentiation by providing (auto) antigenic, costimulatory, and Th17-polarizing cytokine signals. The process to shape and stabilize Th17 development is further promoted by (1) IL-23 and NLRP3 inflammasome-driven IL-1β/IL-18 mainly produced by DCs (as shown in this figure), but also other innate immune cells; (2) TGF-β and IL-21 produced by activated CD4+ T cells; and finally (3) TGF-β produced by Th17 cells themselves in an autocrine manner. This scenario, as reflected by the “IL-1β → IL-23 → IL-17A ↔ TGF-β1 cytokine axis,” represents an important pathway in inflammation-mediated, innate/adaptive immunity-driven fibrogenesis. (DC, dendritic cell; ECM, extracellular matrix; IL, interleukin; IL-R, interleukin receptor; MAPKs, mitogen-activated protein kinases; MHC, major histocompatibility complex; NF-κB, nuclear factor-kappaB; NLRP3, NLR-containing pyrin domain 3; PRRs, pattern recognition receptors; TCR, T cell receptor; TGF-β1, transforming growth factor-beta 1; UCM, up-regulation of costimulatory molecules)

<table>
<thead>
<tr>
<th>Causes of allograft injury</th>
<th>Acute/subacute clinically manifest, subclinical injuries</th>
<th>Persistently, repetitively chronic injuries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonimmune (mechanical, metabolic, organotoxic)-mediated injuries</td>
<td>Donor brain death, postischemic reperfusion injury</td>
<td>Donor senescence, hypertension, hyperlipidemia, hyperglycemia, organotoxic agents</td>
</tr>
<tr>
<td>Allo-/isoimmune (Th1-/Th17-mediated) injuries</td>
<td>Cellular and/or antibody-mediated rejection episodes</td>
<td>Cellular and/or antibody-mediated allo-/isoimmune attacks</td>
</tr>
<tr>
<td>Infection-mediated injuries</td>
<td>Viral, bacterial, fungal infections</td>
<td>Viral infections, e.g., cytomegalovirus BK polyoma virus</td>
</tr>
</tbody>
</table>

Table 1: Causes of allograft injury
as injuries mediated by donor brain death, posts ischemic reperfusion injury (IRI), acute rejection episodes, and infections. Defined chronic risk factors refer to persistently/ repetitively chronic allograft injuries such as subclinically ongoing alloimmune-mediated processes, in particular, alloantibody-mediated attacks, hypertension (methyl-
ical injury), hyperlipidemia (metabolic stress), and administration of organotoxic immunosuppressive drugs such as nephrotoxic calcineurin inhibitors (CNIs).

It is apparent that allograft injury-induced CAD reflects a multifactorial event that, in case of severe cell-destroying insults, results from steadily ongoing loss of functioning parenchymal cells, and, in case of moderate sublytic insults, from accompanying, innate immune-mediated inflammation. Of note, however, in both situations, injury-induced, innate immune-mediated tissue repair mechanisms emerge which aggravate and accelerate the continuously deteriorating allograft function.

In fact, the histologically visible overshooting repair, that is, fibrosing processes such as intima fibrosis (alloatherosclerosis) and interstitial fibrosis (allofibrosis), contribute to CAD whereby the strength of their manifestation may depend on the organ transplanted. For example, alloatherosclerosis is more pronounced in cardiac allografts (coronary artery vasculopathy), whereas allofibrosis is more frequently observed in renal allografts [interstitial fibrosis associated with tubular atrophy (IFTA)]. Probably, both histologically well-defined processes accelerate the progression of CAD as also recently discussed for chronic renal allograft dysfunction. In addition to these two "canonical" processes, there are typical organ-specific lesions associated with CAD such as the bronchiolitis obliterans syndrome following lung transplantation that also reflects an exaggerated repairing response of the donor’s (uncontrolled) innate immune system to injury.

In the following, by focusing on the parameters of clinically well-defined acute and chronic risk factors of CAD, some selected injury-induced innate immune processes, as comprehensively reviewed elsewhere, are briefly explored.

**Early antigen-independent allograft injury**

**Brain death**

A decade ago, early experiments on a rat model of brain death (BD) condition on chronic graft dysfunction. Emerging evidence now indicates that BD conditions, associated with oxidative stress, activate the innate immune system that leads to development of an acute systemic auto-inflammatory syndrome. In fact, documented parameters involved in BD activated innate immune events include DAMPs, PRRs, and signaling molecules, complement fragments, cytokines such as IL-1β, chemokines, and even matured DCs [Table 2]. On the other hand, in studies on a renal isograft model in rats, BD was shown to induce interstitial renal fibrosis. In these studies, fibrosis-inducing factors such as up-regulation of TGF-β were discussed to be important in later progressive fibrotic changes that develop over time in kidney isografts.

**Postischemic reperfusion injury**

The pivotal influence of IRI on CAD is well known from an early clinical study of our group in kidney transplant patients. Production of ROS during IRI has been demonstrated in numerous experiments and also in a clinical study on human renal allografts.

On the other hand, in studies in rats and mice, IRI was shown to induce severe renal fibrosis several weeks after the ROS-induced insult. In studies on a model of murine cardiac isografts, IRI was found to induce atherosclerosis. Moreover, a role of DAMPs and PRRs in IRI-mediated inflammation (including NLRP3 inflammasome-mediated inflammation) has been documented in numerous trials. In fact, there is no doubt that IRI, besides others, leads to the production of proinflammatory cytokines including IL-1β.

**Antigen-dependent allograft injuries**

**Th1 alloimmunity-mediated injury**

If we accept that any injury to an allograft may initiate innate immune events contributing to CAD, one also has

<table>
<thead>
<tr>
<th>Parameters of innate immunity</th>
<th>“Innate” molecules demonstrated in clin./exp. studies on brain death</th>
<th>References (no.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxidative injury</td>
<td>ROS</td>
<td>134, 135</td>
</tr>
<tr>
<td>Complement</td>
<td>C5b-9</td>
<td>141</td>
</tr>
<tr>
<td>DAMPs</td>
<td>HMGB1</td>
<td>137</td>
</tr>
<tr>
<td>TLR4</td>
<td></td>
<td>137</td>
</tr>
<tr>
<td>Signaling molecules</td>
<td>MAPKs</td>
<td>140</td>
</tr>
<tr>
<td>Cytokines</td>
<td>IL-1β</td>
<td>135</td>
</tr>
<tr>
<td>Chemokine receptors</td>
<td>CxCR1, CxCR2</td>
<td>144</td>
</tr>
<tr>
<td>Adhesion molecules</td>
<td>ICAM*</td>
<td>144</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td>Mature DCs</td>
<td>145, 146</td>
</tr>
</tbody>
</table>

*Demonstrated in experimental models of brain death only.

Abbreviations: Clin.: Clinical; DAMPs: Damage-associated molecular patterns; DCs: Dendritic cells; Exp: Experimental; HMGB1: High mobility group box 1; HSP70: Heat shock protein 70; ICAM: Intracellular adhesion molecule 1; IL: Interleukin; JNK: c-Jun NH(2)-terminal kinase; MAPKs: Mitogen-associated protein kinases; PRRs: Pattern recognition receptors; ROS: Reactive oxygen species; TLR: Toll-like receptor; TNF: Tumor necrosis factor
to include specific adaptive alloimmune-mediated injuries induced by acute and/or chronic, T cell–mediated and/or antibody-mediated processes. These alloimmunity-mediated inflammatory injuries, in terms of a feedback loop, can activate innate immune DCs which elicit again an alloimmune response leading to allograft injury (vicious circle) [Figure 8].

Classically, lytic or sublytic injuries, reportedly associated with production of ROS and operating in clinically manifest or subclinically ongoing acute allograft rejection episodes, are thought to be mediated predominantly by CD4+ Th1 cells, cytotoxic CD8+ T cells, and complement-binding alloantibodies. In particular, donor-specific antibodies (DSA)-mediated alloimmunity is currently regarded as an emerging concept of CAD. In fact, DSA cause profound changes not only in ECs of the allograft (micro) vasculature but also in allograft bronchioles, thereby fulfilling the prerequisite for induction of DAMPs to initiate fibrogenic innate immune processes. Of note, in the early phase of a Th1 alloimmune response, involvement of the Th17 cell lineage has recently been described to secrete IL-17 which appears to primarily facilitate the recruitment of leukocytes into the graft, thereby contributing to acute rejection (see below). Finally, there is already preliminary evidence in support of the notion that injury to donor ECs induced by non–MHC-, anti-EC isoantibodies or alloantibodies may contribute to innate immune-mediated alloatherosclerosis.

Of note, the first experimental studies on various acute and chronic rejection models provided evidence supporting a role for adaptive alloimmune responses in activating innate immune responses via induction of DAMPs such as HMGB1 and HSPs, that is, agonists for TLR2/TLR4 and RAGE. In another line of experiments, DAMP (cytosolic DNA)-activated human DCs were found to be potent activators of the adaptive immune response. In support of this observation is a study on a model of cardiac allograft rejection demonstrating up-regulation of the apoptosis-related inflammasome. Moreover, recent experiments demonstrated that HMGB1 induces IL-17–producing T cells to mediate the early stage of cardiac allograft rejection in mice. Together, these new findings provide first clues that the NLRP3 inflammasome is already activated during alloimmune-mediated acute rejection episodes to start contributing to the establishment of the innate fibrogenic IL-1β → IL-23 → IL-17A ↔ TGF-β1 cytokine axis.

Figure 8: Scenario model: allograft injury-induced, innate immune-mediated chronic allograft dysfunction. Multiple acute and chronic allograft injuries, caused by allo- and isoinnune responses and/or noninnune-mediated conditions (mechanical, metabolic, and oxidative stress) and/or infections, activate donor-derived innate immune cells (such as intragraft vascular cells, fibroblasts, and epithelial cells) and recipient-derived cells (such as graft-invading macrophages and leukocytes). The activated innate immune system responds to those various insults with allograft inflammation that, in turn, promotes development of alloatherosclerosis and allofibrosis. Together with injury-induced, cell death–associated atrophy, these innate immune events ultimately lead to chronic allograft dysfunction. Note the vicious circle of this scenario: Allograft injuries activate the innate immune system that elicits an adaptive allo- and isoinnune response leading to immune-mediated allograft injury that, in turn, activates the innate immune system again. (alloMHC, donor major histocompatibility complex; DC, dendritic cells; HLA, human leukocyte antigens; neoAgs, neoantigens)
In addition, DAMPs such as oxidation-specific DAMPs and/or injury-induced DAMPs such as HMGB1 and HSPs demonstrated in acute and chronic rejection models\cite{166-169} may well act in terms of “NLRP3 inflammasome-priming” DAMPs that, in cooperation with cholesterol crystals or other “NLRP3 inflammasome-activating” DAMPs, are able to create an inflammatory milieu in the donor (micro) vasculature, contributing to alloatherogenesis, a scenario that has been discussed in quite a similar way elsewhere,\cite{173} and is emphasized in regard to native atherosclerosis in more recently published reports.\cite{174,175}

Thus, although experimental and clinical data in support of such a concept are still sparse, one may discuss the possibility that acute and persistently/repetitively chronic adaptive alloimmune processes may promote the development of innate immune-mediated fibrotic processes as reflected by alloatherosclerosis and interstitial allofibrosis.

**Th17 isoimmunity-mediated injury**

The establishment of *de novo* Th17 autoimmunity/autoreactivity that, besides Th1-type alloimmunity/alloreactivity, contributes to development of CAD is increasingly appreciated.\cite{163,176} From a recipient’s view, this phenomenon occurring in the organ of another person may rather be called *de novo* isoimmunity. Increasing experimental and clinical evidence suggests that Th17 immunity, already known to contribute to development of both autoimmune diseases and acute allograft rejection, plays a critical role in CAD,\cite{112,163,176} but, notably, is resistant to CNI-based immunosuppression.\cite{177}

Th17 immunity-mediated injury appears to be predominately conveyed via secretion of cytokines including IL-17A, IL-17F, IL-21, and IL-22, which contribute to recruitment of immune cells, in particular, neutrophils, to sites of injury and lead to induction of DAMPs which, in turn, may activate innate immune cells such as DCs, fibroblasts, epithelial cells, and vascular cells. In addition, IL-17, in coordination with IL-21 and B cell activating factor of the TNF family (BAFF), promotes germinal center formation and influences B cells to produce pathogenic antibodies,\cite{112,178} a process that may add further injury to an allograft [Figure 8]. Most important, however, the secretion of IL-17 may lead to alloglobosis via contribution to the innate IL-1β → IL-23 → IL-17A ↔ TGF-β1 cytokine axis mentioned above [Figure 7].

As reviewed,\cite{118} PRRs expressed by DCs including TLRs and NLRs are essential to sense Th17-instructive DAMPs. These DAMPs, as demonstrated for HMGB1, may be induced by allograft injuries, in particular, by previous Th1 alloimmune response-mediated injury.\cite{169,179} Further, cytokine receptors and other immunomodulatory receptors also contribute to DC-mediated Th17 cell differentiation by affecting the production of Th17-polarizing cytokines.\cite{118} As also reviewed,\cite{118} activation of NLPR3-mediated inflammasome has been shown to promote Th17 cell differentiation in autoimmune and inflammatory models. This is mechanistically believed to be linked to the requirement of NLRP3 to promote IL-1β and IL-18 production from DCs for the potentiation of Th17 responses. These findings indicate that diverse recognition receptors in DCs triggered by certain selected DAMPs, including “NLRP3 inflammasome-activating” DAMPs such as adenosine released from injured graft cells,\cite{180} translate inflammatory mediators and environmental signals into proper Th17 cell generation.

Interestingly, Th17 immunity appears to be mainly directed against non-human leukocyte antigens (non-HLA) rather than against MHC/HLA alloantigens. In fact, a number of altered-self tissue antigens have emerged as targets of isoimmune responses after transplantation and vary depending on the transplanted organ. These isoantigens that are presented to naïve T cells by recipient DCs via the indirect pathway of allore cognition can be regarded as the result of intermolecular epitope spreading (in terms of allograft injury-induced exposure of “cryptic self–antigens”) that was also demonstrated during chronic allograft rejection.\cite{181} These tissue-specific isoantigens reportedly involved in CAD include cardiac myosin, HSPs, vimentin, collagen type V, and K-α1 tubulin.\cite{164,176} Remarkably, clinical studies in recipients with cardiac allograft vasculopathy already demonstrated that Th17 cells specific to myosin, vimentin, Col-V, and K-α1T are involved in CAD.\cite{164,182}

**Chronic antigen-independent injuries**

**Hypertension**

In a state of chronic hypertension that itself is supposed to originate from primary innate/adaptive immune responses\cite{183} the vessel wall is permanently injured, predominantly mediated by increased hemodynamic forces, that is, increased shear stress associated with oxidative stress and pathological stretch determined by luminal pressure.\cite{184,185} In turn, mechanical and oxidative stress in the vasculature may lead to the induction of DAMPs which initiate innate fibrogenic pathways and thereby promote atherogenesis.\cite{131,183,186}

For example, in studies on *in vitro* stretching models of pulmonary epithelial cells and aortic smooth muscle cells, the stretch forces were shown to lead the DAMPs, HMGB1 and oxLDL,\cite{187,188} In addition, as shown in an experimental system consisting of rat arterial endothelial sheets exposed to tensile stretch stress, the expression of the endothelial DAMP, HSP70, was markedly up-regulated.\cite{188} In other lines of studies, the DAMP, HMGB1, was found to play a role in the pathogenesis of hypertension.\cite{190,191} On the other hand, hypertension/mechanical stress-induced PRRs such as TLR2, TLR4, and RAGE, known to recognize mechanical stress-induced DAMPs, have also been demonstrated to be involved in atherogenesis [Figure 4].\cite{131,192-195}
Of note, hypertension may also contribute to interstitial fibrogenesis as documented in experimental and clinical studies. Modern notions about potential hypertension-induced fibrogenesis include the discussion about mechanisms resulting in tissue hypoxia that, in turn, induced fibrosis. In renal fibrosis, for example, such mechanisms include hypertension-associated decreased renal blood flow due to increased vascular tone which is induced by angiotensin II that limits oxygen delivery. Notably, this process is associated with hypoxia and increases oxidative stress. Once fibrosis has developed, a vicious circle may be generated relating tubule-interstitial fibrosis to chronic hypoxia, which creates a self-sustaining mechanism that accelerates the fibrogenic process.

**Dyslipidemia**

Lipid abnormalities are a common complication of transplantation, occurring in up to 60% of kidney transplanted patients. Following transplantation, lipid disturbances may show a different profile due to the various effects of immunosuppressive drugs on lipid metabolism. Accordingly, steroids, CNIs, and mammalian target of rapamycin (mTOR) inhibitors usually lead to quantitative and qualitative abnormalities of very low-density, low-density, and high-density lipoproteins. These proatherogenic lipid abnormalities (e.g., cholesterolemia), if suboptimally treated, may lead to cardiovascular complications as one of the leading causes of death in transplant recipients and, in addition, may promote CAD via contribution to alloatherogenesis [Figures 3 and 4].

As outlined in more detail above, oxidized lipids such as oxLDL enriched in dyslipidemia may contribute to atherogenesis/alloatherogenesis via activation of innate immune pathways resulting in creation of arterial wall inflammation.

**Organotoxic drugs**

Organotoxic (e.g., nephrotoxic) and atherogenic immunosuppressive agents such as CNIs contribute to the development of CAD. There are numerous reports in the literature from experiments clearly showing an atherogenic effect of cyclosporine A (CsA), as indicated by induction of endothelial dysfunction, EC injury, and arteritis. As reviewed elsewhere, CsA can induce the generation of ROS (in particular, free hydroxyl radicals in kidneys of CsA-treated rats) and HSPs induced by ROS, respectively. In regard to CsA-mediated renal fibrosis, targeted studies revealed that the proximal tubular epithelial cells themselves are direct targets for CsA-induced injury. As a matter of fact, evidence was provided suggesting that CsA can cause an EMT-like event in human renal epithelial cells.

On the other hand, there is accumulating evidence suggesting that CNI-induced chronic global injury to renal allografts activates cells of innate immunity (i.e., vascular cells, epithelial cells, and fibroblasts/myofibroblasts) via chronic oxidative stress. In this scenario, ROS-induced DAMPs such as HSPs may operate as endogenous ligands of PRR-bearing renal cells, a notion that has experimentally been confirmed.

Taken together, and in view of these experimental data, one may discuss that long-term application of CNIs in kidney transplant patients accelerates the process of chronic allograft nephropathy via innate immune-mediated alloatherogenesis and allofibrogenesis.

**Infection-mediated allograft injuries**

Certain infectious diseases in transplant patients appear to be associated with CAD. In kidney transplant patients, this group preferentially includes urinary tract bacterial infections as well as nephropathy due to BK polyoma virus infection which activates the innate immune defense system through TLR3, contributing to intrarenal antiviral and anti-inflammatory responses. On the other hand, there is a considerable number of different infectious agents that have been linked with an increased risk of cardiovascular disease, including *C. pneumonia*, influenza A virus, HCV, and CMV. As documented, *C. pneumonia*, CMV, and HCV infections have been identified as the risk factors for CAD.

In regard to the underlying mechanisms of how a pathogen may contribute to alloatherogenesis or allofibrogenesis, a role for a direct pathogenic cytotoxic effect and an indirectly mediated effect via an anti-pathogen innate immune response eventually associated with collateral allograft damage, respectively, may be causative, as also discussed elsewhere. Another mechanism currently discussed refers to the possibility that infectious pathogens, via associated tissue injury, may lead to the induction of DAMPs which, in turn, result in an innate/adaptive immune response against host tissue, here the allograft [Figure 2].

**Outlook**

As already proposed by us two decades ago, convincing evidence has now accumulated in support of the notion that CAD results from multiple acute and/or persistently/ repetitively chronic injuries to an allograft. Such injuries are predominately caused by (1) an adaptive Th1 alloimmune response and, as increasingly appreciated, an adaptive Th17 isomorphic response, as well as (2) nonimmune antigen-independent attacks and (3) infection-mediated insults that may accelerate progression of dysfunction. Over time, exposure of an allograft to those various injurious attacks, in particular, when repeatedly occurring, leads – or at least contributes – to both progressive loss of functioning parenchymal cells and innate immunity/inflammation-mediated fibrosing processes of the (micro) vasculature and interstitium which, in turn, contribute to further loss of parenchymal...
cells. The NLRP3 inflammasome appears to play a dominant role in fibrogenesis, but other inflammasomes such as the AIM2 inflammasome may also contribute.

Emerging concepts of how to interfere with (1) those different injuries, (2) generation of DAMPs, and (3) subsequent PRR-mediated signaling pathways leading to fibrosis should guide us to innovative therapeutic approaches to tackle specifically this cardinal clinical problem in transplantation medicine. Certainly, various concepts can be considered. With respect to resistance of Th17 immunity to nephrotoxic CNIs,\textsuperscript{[217]} one example out of – quite admittedly – many potential strategies would refer to prophylactic treatment of infections in transplant patients (such as CMV or BK polyoma virus infection) with intravenous hyperimmune or standard immunoglobulin G preparations because, besides their antiviral properties, these biologicals exert immunosuppressive potency,\textsuperscript{[216]} induce Tregs via “Tregitopes” on DCs,\textsuperscript{[217]} and, importantly, have recently been shown to inhibit IL-17 production by Th17 cells involved in CAD.\textsuperscript{[218]}

REFERENCES

High-mobility group box protein 1 neutralization reduces β-inflammasomes: Sensors of metabolic stresses for vascular...
Chronic allograft dysfunction: A model disorder of innate immunity

IL-1 and IL-23 mediate early IL-17A production in

Paradoxical function for the receptor for

β

September - October 2013

81. Cai WF, Zhang XW, Yan HM, Ma YG, Wang XX, Yan J, et al. Inhibition of


β


58. Hofgaroam CM, Trujillo G, Martinez FJ. Aberrant innate immune sensing leads to the rapid progression of idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2012;5 Suppl 1:533-54.2


45. Hofgaroam CM, Trujillo G, Martinez FJ. Aberrant innate immune sensing leads to the rapid progression of idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2012;5 Suppl 1:533-54.2


Walter Gottlieb Land

Chronic allograft dysfunction: A model disorder of innate immunity


